Medical
Pharmaceutical
Research And Development
Madrigal Pharmaceuticals
$140.099876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$140.09
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$3.75 (-2.61%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell MDGL and other stocks, options, ETFs, and crypto commission-free!
About
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Read More The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
Employees
17
Headquarters
West Conshohocken, Pennsylvania
Founded
2011
Market Cap
2.22B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
284.26K
High Today
$144.00
Low Today
$137.12
Open Price
$143.74
Volume
54.00K
52 Week High
$325.98
52 Week Low
$91.56
Collections
Medical
Pharmaceutical
Research And Development
Health
Cancer Prevention
Technology
News
MarketBeatFeb 27
Stock Price, News, & Analysis for Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is a...
Price Paid on Robinhood
10% Lower
Right Now
52 Week Low
$91.56
Average Price Paid
$156.29
52 Week High
$325.98
Earnings
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 7, Pre-Market